Equites Radar

AZTA · Azenta, Inc.

Medical Instruments & SuppliesUnited StatesAnalyst view: Buy

$27.37

+5.12% last session

End-of-day data · updated 2026-07-28

Mildly bullish3 bullish · 1 bearish technical signals
Consensus: Buy (2.17 from 5 analysts)
To mean target: +1.6%

Market cap

$1B

Enterprise value

$1B

Trailing P/E

Forward P/E

44.8

Dividend yield

Beta

1.37

Avg volume

1M

Employees

3K

2D change

5D change

-2.76%

10D change

4.68%

30D change

7.92%

60D change

20.28%

MTD change

5.08%

YTD change

-17.26%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.17
Covering analysts5
Mean price target$27.80
Low price target$20.00
Upside to mean target+1.6%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)69.5
50-day MA$23.75
200-day MA$28.08
Price vs 50-day MA+21.8%
Price vs 200-day MA+3.0%
MACD histogram0.13
Volume vs 3-month avg0.6×
52w low $16.0252w high $41.01

Analyst sentiment over time — AZTA

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-05-06

Latest call per bank · past 12 months

Jefferies

Buy

$40.00

+46.1% vs price
▼ cut from $42.00Maintains · 2026-02-04

Recent rating actions

DateFirmActionRatingPrice target
2026-05-06NeedhamMaintainsBuy$44.00 $33.00
2026-04-06Evercore ISI GroupMaintainsOutperform$45.00 $35.00
2026-03-17NeedhamReiteratesBuy$44.00
2026-02-05Evercore ISI GroupMaintainsOutperform$50.00 $45.00
2026-02-04JefferiesMaintainsBuy$42.00 $40.00
2026-02-04NeedhamReiteratesBuy$44.00
2026-01-08TD CowenMaintainsHold$35.00 $39.00
2026-01-05Evercore ISI GroupUpgradeIn-LineOutperform$34.00 $50.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 70 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 21.8% above the 50-day MA ($23.75).
  • Price vs 200-day MA: Trading 3.0% above the 200-day MA ($28.08).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.13) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($16.02) and high ($41.01).

AZTA Price Chart

Loading chart for AZTA

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$33.73
Net debt / EBITDA-8.9
WACC13.0%
Revenue growth1.00%
Earnings growth

About Azenta, Inc.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

More in Medical Instruments & Supplies

Screen AZTA against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.